Physician profile

Dennis Min

Gastroenterology (Internal Medicine) · Middletown, OH

NPI 1104808518

$126,783.47

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $36,015.14 2019
Allergan, INC. $33,189.26 2019
Romark Laboratories, Lc $19,606.13 2019-2020
Daiichi Sankyo INC. $15,245.25 2019-2020
Abbvie INC. $10,531.17 2019
Concordia Pharmaceuticals INC. $7,979.64 2019
Parapro, LLC $2,933.09 2019
Vertex Pharmaceuticals Incorporated $383.33 2021
Redhill Biopharma INC. $213.57 2020
Pfizer INC. $151.82 2019
Otsuka America Pharmaceutical, INC. $128.40 2019
Ironwood Pharmaceuticals, INC $84.63 2019
Gilead Sciences, INC. $80.96 2019-2020
Biodelivery Sciences International, INC. $44.71 2019-2020
Alfasigma USA, INC. $31.04 2020
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Ucb, INC. $29.78 2020
Takeda Pharmaceuticals U.S.A., INC. $26.61 2019
Medtronic USA, INC. $25.13 2020
Nestle Healthcare Nutrition INC. $22.10 2020
Intercept Pharmaceuticals, INC. $21.24 2020
Evoke Pharma, INC. $18.15 2020
Olympus America INC. $13.52 2019
Qol Medical, LLC $8.80 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dennis Min

$126,783.47

in general payments reported 2019-2025

Years
2019-2021
Top company
Salix Pharmaceuticals, A Division of Bausch Health US, LLC

https://glasscript.com/doctor/276667/dennis-min

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.